Fabrazyme shows promise for fabry disease in chinese study
NCT ID NCT05054387
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested the safety and effectiveness of Fabrazyme (agalsidase beta) in 22 Chinese patients with Fabry disease, a rare genetic disorder. Participants received enzyme replacement therapy through IV infusions over 54 weeks. The study monitored side effects and changes in disease markers like lyso-GL3 and GL3 levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fabrazyme (agalsidase beta)
What this could lead to
If successful, this could confirm that Fabrazyme is safe and effective for Chinese patients with Fabry disease, providing a treatment option to manage the condition.
What could go wrong
This is a small, single-arm study with only 22 participants, so results may not apply to all patients. As an enzyme replacement therapy, it requires ongoing infusions and does not cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :1560001
Shanghai, 200025, China
-
Investigational Site Number :1560002
Beijing, 100730, China
-
Investigational Site Number :1560003
Beijing, 100034, China
-
Investigational Site Number :1560004
Shanghai, 201102, China
-
Investigational Site Number :1560005
Wuhan, 016040, China
-
Investigational Site Number :1560006
Taiyuan, 030001, China